DK0873407T3 - Apo-2-ligand - Google Patents

Apo-2-ligand

Info

Publication number
DK0873407T3
DK0873407T3 DK97903760T DK97903760T DK0873407T3 DK 0873407 T3 DK0873407 T3 DK 0873407T3 DK 97903760 T DK97903760 T DK 97903760T DK 97903760 T DK97903760 T DK 97903760T DK 0873407 T3 DK0873407 T3 DK 0873407T3
Authority
DK
Denmark
Prior art keywords
ligand
apo
cytokine
antibodies
induce
Prior art date
Application number
DK97903760T
Other languages
English (en)
Inventor
Avi J Ashkenazi
Anan Chuntharapai
Kyung Jin Kim
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of DK0873407T3 publication Critical patent/DK0873407T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/14—Lymphokine; related peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/14—Lymphokine; related peptides
    • Y10S930/144—Tumor necrosis factor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Furan Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK97903760T 1996-01-09 1997-01-08 Apo-2-ligand DK0873407T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/584,031 US6030945A (en) 1996-01-09 1996-01-09 Apo-2 ligand
PCT/US1997/000272 WO1997025428A1 (en) 1996-01-09 1997-01-08 Apo-2 ligand

Publications (1)

Publication Number Publication Date
DK0873407T3 true DK0873407T3 (da) 2007-09-24

Family

ID=24335618

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97903760T DK0873407T3 (da) 1996-01-09 1997-01-08 Apo-2-ligand

Country Status (12)

Country Link
US (1) US6030945A (da)
EP (3) EP1734122A3 (da)
JP (4) JP2001510321A (da)
AT (1) ATE362985T1 (da)
AU (1) AU729279B2 (da)
CA (2) CA2241572C (da)
DE (1) DE69737747T2 (da)
DK (1) DK0873407T3 (da)
ES (1) ES2287948T3 (da)
IL (3) IL125168A0 (da)
PT (1) PT873407E (da)
WO (1) WO1997025428A1 (da)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU708239B2 (en) * 1995-06-29 1999-07-29 Immunex Corporation Cytokine that induces apoptosis
US6284236B1 (en) * 1995-06-29 2001-09-04 Immunex Corporation Cytokine that induces apoptosis
US20050089958A1 (en) * 1996-01-09 2005-04-28 Genentech, Inc. Apo-2 ligand
US6998116B1 (en) 1996-01-09 2006-02-14 Genentech, Inc. Apo-2 ligand
US20040038347A1 (en) * 1996-03-14 2004-02-26 Human Genome Sciences, Inc. Apoptosis inducing molecule I
US6777217B1 (en) 1996-03-26 2004-08-17 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto
CA2256464A1 (en) * 1996-06-07 1997-12-11 Amgen Inc. Tumor necrosis factor-related polypeptide
US6342369B1 (en) 1997-05-15 2002-01-29 Genentech, Inc. Apo-2-receptor
EP2083079A1 (en) * 1997-06-18 2009-07-29 Genentech, Inc. Apo-2DcR
US6346388B1 (en) 1997-08-13 2002-02-12 Smithkline Beecham Corporation Method of identifying agonist and antagonists for tumor necrosis related receptors TR1 and TR2
WO1999014330A1 (en) 1997-09-18 1999-03-25 Genentech, Inc. DcR3 POLYPEPTIDE, A TNFR HOMOLOG
EP1021542B1 (en) 1997-10-10 2009-03-04 Genentech, Inc. Apo-3 ligand
US6740739B1 (en) * 1998-01-15 2004-05-25 Genentech, Inc. Substitutional variants of APO-2 ligand
AU2338299A (en) 1998-01-26 1999-08-09 Genentech Inc. Antibodies to death receptor 4 (dr4) and uses thereof
NZ525914A (en) 1998-03-10 2004-03-26 Genentech Inc Novel polypeptides and nucleic acids encoding the same
EP1941905A1 (en) 1998-03-27 2008-07-09 Genentech, Inc. APO-2 Ligand-anti-her-2 antibody synergism
JP2002507404A (ja) * 1998-03-27 2002-03-12 ジェネンテク・インコーポレイテッド Ａｐｏ−２リガンド−抗ＨＥＲ−２抗体相乗作用
US6252050B1 (en) * 1998-06-12 2001-06-26 Genentech, Inc. Method for making monoclonal antibodies and cross-reactive antibodies obtainable by the method
EP2058334B1 (en) * 1998-06-12 2012-10-31 Genentech, Inc. Monoclonal antibodies, cross-reactive antibodies and method for producing the same
ES2274656T3 (es) * 1998-11-23 2007-05-16 Centre National De La Recherche Scientifique Factor inductor de apoptosis.
US6773911B1 (en) 1998-11-23 2004-08-10 Amgen Canada Inc. Apoptosis-inducing factor
US6534061B1 (en) 1999-04-12 2003-03-18 Genentech, Inc. Tumor necrosis factor receptor homologs and nucleic acids encoding the same
EP1873244A3 (en) * 1999-06-02 2008-04-02 Genentech, Inc. Methods and compositions for inhibiting neoplastic cell growth
ATE330972T1 (de) * 1999-06-09 2006-07-15 Genentech Inc Apo-2l rezeptor-agonist und cpt-11 synergie- effekt
EP1658859A1 (en) * 1999-06-09 2006-05-24 Genentech, Inc. APO-2L receptor agonist and CPT-11 synergism
CN101633692A (zh) * 1999-06-28 2010-01-27 杰南技术公司 利用二价金属离子制备Apo-2配体的方法
CA2396793A1 (en) 2000-02-16 2001-08-23 Genentech, Inc. Uses of agonists and antagonists to modulate activity of tnf-related molecules
US20030129724A1 (en) 2000-03-03 2003-07-10 Grozinger Christina M. Class II human histone deacetylases, and uses related thereto
CN101289511A (zh) 2000-04-11 2008-10-22 杰南技术公司 多价抗体及其应用
US6900185B1 (en) * 2000-04-12 2005-05-31 University Of Iowa Research Foundation Method of inducing tumor cell apoptosis using trail/Apo-2 ligand gene transfer
PT1303293E (pt) 2000-07-27 2009-03-11 Genentech Inc Administração sequencial de cpt-11 e polipéptido apo-2l
CA2426762A1 (en) * 2000-11-02 2002-05-10 Sloan-Kettering Institute For Cancer Research Methods for enhancing the efficacy of cytotoxic agents through the use of hsp90 inhibitors
JP2002306170A (ja) * 2001-04-06 2002-10-22 Jenokkusu Soyaku Kenkyusho:Kk アレルギー性疾患の検査方法
US7244853B2 (en) 2001-05-09 2007-07-17 President And Fellows Of Harvard College Dioxanes and uses thereof
WO2003066661A2 (en) 2001-07-03 2003-08-14 Genentech, Inc. Human dr4 antibodies and uses thereof
IL161051A0 (en) * 2001-10-02 2004-08-31 Genentech Inc Apo-2 ligand variants and uses thereof
ES2351786T3 (es) 2001-11-13 2011-02-10 Genentech, Inc. Formulaciones con ligando apo2/trail y usos de las mismas.
US7842668B1 (en) 2001-11-13 2010-11-30 Genentech, Inc. Apo-2 ligand/trail formulations
US7741285B2 (en) * 2001-11-13 2010-06-22 Genentech, Inc. APO-2 ligand/trail formulations
CA2489348A1 (en) 2002-06-24 2003-12-31 Genentech, Inc. Apo-2 ligand/trail variants and uses thereof
EP1558631A4 (en) * 2002-10-30 2006-10-04 Pfizer Prod Inc METHOD AND COMPOSITIONS FOR THE DIAGNOSIS AND TREATMENT OF CANCER IN PETS
CN101039957A (zh) 2003-05-16 2007-09-19 因特缪恩公司 合成的趋化因子受体配体及其使用方法
PL1631313T3 (pl) 2003-06-05 2015-08-31 Genentech Inc Terapia skojarzona zaburzeń z komórek B
US7407973B2 (en) 2003-10-24 2008-08-05 Intermune, Inc. Use of pirfenidone in therapeutic regimens
RU2433185C2 (ru) 2004-03-11 2011-11-10 Дженентек, Инк. Способ получения полипептидов
US20080274955A1 (en) * 2004-04-13 2008-11-06 Kyungpook National University Industry Academic Cooperation Foundation Novel Use of a Polypeptide Comprising Fas-1 Domain
MX2007001469A (es) 2004-08-06 2007-03-26 Genentech Inc Ensayos y metodos que utilizan biomarcadores.
AU2012200601B2 (en) * 2004-08-06 2012-10-11 Genentech, Inc. Assays and methods using biomarkers
PL1774037T3 (pl) 2004-08-06 2011-09-30 Genentech Inc Oznaczenia i sposoby wykorzystujące biomarkery
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
BRPI0515615A (pt) * 2004-09-08 2008-07-29 Genentech Inc métodos para tratar células cancerosas e doença imune relacionada
KR20070050951A (ko) * 2004-09-08 2007-05-16 제넨테크, 인크. 사멸 수용체 리간드 및 ｃｄ20 항체의 사용 방법
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
US8029783B2 (en) * 2005-02-02 2011-10-04 Genentech, Inc. DR5 antibodies and articles of manufacture containing same
US20060188498A1 (en) 2005-02-18 2006-08-24 Genentech, Inc. Methods of using death receptor agonists and EGFR inhibitors
CN101495116A (zh) 2005-03-22 2009-07-29 哈佛大学校长及研究员协会 蛋白降解病症的治疗
JP5186372B2 (ja) 2005-08-16 2013-04-17 ジェネンテック， インコーポレイテッド 細胞／組織においてｇａｌｎａｃ−ｔ１４発現を試験することによるａｐｏ２ｌ／ｔｒａｉｌに対するアポトーシス感受性
WO2007062090A2 (en) 2005-11-23 2007-05-31 Genentech, Inc. Methods and compositions related to b cell assays
AU2007214458C1 (en) 2006-02-14 2012-12-06 Dana-Farber Cancer Institute, Inc. Histone deacetylase inhibitors
AU2007345292B2 (en) 2006-02-14 2013-10-31 Dana-Farber Cancer Institute, Inc. Bifunctional histone deacetylase inhibitors
CA2654540C (en) * 2006-05-03 2017-01-17 President And Fellows Of Harvard College Histone deacetylase and tubulin deacetylase inhibitors
EP2200631A1 (en) 2007-10-16 2010-06-30 Zymogenetics, Inc. Combination of blys inhibition and anti-cd 20 agents for treatment of autoimmune disease
GB0724532D0 (en) * 2007-12-17 2008-01-30 Nat Univ Ireland Trail variants for treating cancer
RU2515611C2 (ru) * 2008-07-23 2014-05-20 Президент Энд Феллоуз Оф Гарвард Колледж Ингибиторы деацетилазы и их применение
JP5773879B2 (ja) 2008-11-25 2015-09-02 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． 神経系の細胞の生存を促進するためのＤＲ６およびｐ７５のアンタゴニストの使用
AU2010252012A1 (en) * 2009-05-27 2011-12-22 Glaxosmithkline Biologicals S.A. CASB7439 constructs
WO2010146059A2 (en) 2009-06-16 2010-12-23 F. Hoffmann-La Roche Ag Biomarkers for igf-1r inhibitor therapy
CN104059955A (zh) 2009-08-11 2014-09-24 弗·哈夫曼-拉罗切有限公司 在无谷氨酰胺的细胞培养基中的蛋白质生产
WO2011019393A2 (en) 2009-08-11 2011-02-17 President And Fellows Of Harvard College Class- and isoform-specific hdac inhibitors and uses thereof
ES2356880B8 (es) * 2009-08-21 2012-10-30 Universidad De Zaragoza Liposomas recubiertos con el dominio extracelular de la proteína apo2l/trail.
WO2011043835A1 (en) * 2009-10-09 2011-04-14 Anaphore, Inc. Polypeptides that bind il-23r
WO2012042480A1 (en) 2010-09-28 2012-04-05 Kahr Medical Ltd. Compositions and methods for treatment of hematological malignancies
US20140178398A1 (en) * 2011-05-03 2014-06-26 Genentech, Inc Vascular disruption agents and uses thereof
CN103534273B (zh) 2011-09-16 2020-05-12 北京沙东生物技术有限公司 环化变构trail/apo2l及其编码基因与应用
HRP20200100T1 (hr) 2014-02-27 2020-04-03 F. Hoffmann - La Roche Ag Modulacija rasta i glikozilacije stanica u rekombinantnoj proizvodnji glikoproteina
US11279768B1 (en) 2015-04-03 2022-03-22 Precision Biologics, Inc. Anti-cancer antibodies, combination therapies, and uses thereof
HRP20250951T1 (hr) 2015-12-30 2025-10-10 F. Hoffmann-La Roche Ag Formulacije sa smanjenom razgradnjom polisorbata
EP3947454A1 (en) * 2019-03-27 2022-02-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Recombinant proteins with cd40 activating properties
EP4136212A1 (en) 2020-04-15 2023-02-22 Genentech, Inc. Method for medium treatment before inoculation
CR20220531A (es) 2020-04-24 2022-11-28 Hoffmann La Roche Modulacion de enzimas y vías con compuestos de sulfhidrilo y sus derivados
PE20231556A1 (es) 2020-11-16 2023-10-03 Hoffmann La Roche Glucoformas de fab ricas en manosa

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE266710C (da) *
US3691016A (en) * 1970-04-17 1972-09-12 Monsanto Co Process for the preparation of insoluble enzymes
CA1023287A (en) * 1972-12-08 1977-12-27 Boehringer Mannheim G.M.B.H. Process for the preparation of carrier-bound proteins
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4195128A (en) * 1976-05-03 1980-03-25 Bayer Aktiengesellschaft Polymeric carrier bound ligands
US4330440A (en) * 1977-02-08 1982-05-18 Development Finance Corporation Of New Zealand Activated matrix and method of activation
CA1093991A (en) * 1977-02-17 1981-01-20 Hideo Hirohara Enzyme immobilization with pullulan gel
US4206226A (en) * 1977-08-29 1980-06-03 The United States Of America As Represented By The Department Of Health, Education And Welfare Use of 4-carboxy-phthalato-(1,2-diaminocyclohexane)-platinum(II) and alkali metal salts thereof in alleviating L1210 murine leukemia
FR2413974A1 (fr) * 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4229537A (en) * 1978-02-09 1980-10-21 New York University Preparation of trichloro-s-triazine activated supports for coupling ligands
JPS6023084B2 (ja) * 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4342566A (en) * 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
US4399216A (en) * 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
ZA811368B (en) * 1980-03-24 1982-04-28 Genentech Inc Bacterial polypedtide expression employing tryptophan promoter-operator
US4419446A (en) * 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
NZ201705A (en) * 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4640835A (en) * 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4870009A (en) 1982-11-22 1989-09-26 The Salk Institute For Biological Studies Method of obtaining gene product through the generation of transgenic animals
US4601978A (en) * 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4713339A (en) * 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
AU2353384A (en) * 1983-01-19 1984-07-26 Genentech Inc. Amplification in eukaryotic host cells
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4496689A (en) * 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4965199A (en) * 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4736866B1 (en) 1984-06-22 1988-04-12 Transgenic non-human mammals
DE3675588D1 (de) * 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US4676980A (en) * 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
AU597574B2 (en) * 1986-03-07 1990-06-07 Massachusetts Institute Of Technology Method for enhancing glycoprotein stability
US4791192A (en) * 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5010182A (en) * 1987-07-28 1991-04-23 Chiron Corporation DNA constructs containing a Kluyveromyces alpha factor leader sequence for directing secretion of heterologous polypeptides
IL87737A (en) * 1987-09-11 1993-08-18 Genentech Inc Method for culturing polypeptide factor dependent vertebrate recombinant cells
GB8724885D0 (en) * 1987-10-23 1987-11-25 Binns M M Fowlpox virus promotors
EP0321196A3 (en) * 1987-12-18 1990-07-18 Mycogen Plant Science, Inc. 780 t-dna gene transcription activator
ATE105585T1 (de) * 1987-12-21 1994-05-15 Univ Toledo Transformation von keimenden pflanzensamen mit hilfe von agrobacterium.
AU4005289A (en) * 1988-08-25 1990-03-01 Smithkline Beecham Corporation Recombinant saccharomyces
FR2646437B1 (fr) * 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
ES2096590T3 (es) * 1989-06-29 1997-03-16 Medarex Inc Reactivos biespecificos para la terapia del sida.
DK168302B1 (da) * 1989-06-29 1994-03-07 Danisco Fremgangsmåde til indføring af molekyler, især genetisk materiale i planteceller
ATE194384T1 (de) * 1989-09-12 2000-07-15 Hoffmann La Roche Tnf-bindende proteine
ES2083469T3 (es) * 1989-11-22 1996-04-16 Genentech Inc Peptido asociado a una latencia y utilizaciones del mismo.
US5206161A (en) * 1991-02-01 1993-04-27 Genentech, Inc. Human plasma carboxypeptidase B
EP0586505A1 (en) * 1991-05-14 1994-03-16 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
WO1993008829A1 (en) * 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
EP0656064B1 (en) * 1992-08-17 1997-03-05 Genentech, Inc. Bispecific immunoadhesins
AU6852594A (en) * 1993-06-03 1995-01-03 Therapeutic Antibodies Inc. Production of antibody fragments
NZ275711A (en) * 1993-10-14 1998-03-25 Immunex Corp Monoclonal antibodies and binding proteins which bind to human fas antigen (nerve growth factor/tumour necrosis factor receptor type)
AU7983294A (en) * 1993-10-19 1995-05-08 Regents Of The University Of Michigan, The P53-mediated apoptosis
IL111125A0 (en) * 1994-05-11 1994-12-29 Yeda Res & Dev Soluble oligomeric tnf/ngf super family ligand receptors and their use
AU708239B2 (en) * 1995-06-29 1999-07-29 Immunex Corporation Cytokine that induces apoptosis
AU5711196A (en) * 1996-03-14 1997-10-01 Human Genome Sciences, Inc. Apoptosis inducing molecule i
CA2256464A1 (en) * 1996-06-07 1997-12-11 Amgen Inc. Tumor necrosis factor-related polypeptide

Also Published As

Publication number Publication date
JP2005237370A (ja) 2005-09-08
EP1889915A1 (en) 2008-02-20
ATE362985T1 (de) 2007-06-15
CA2241572A1 (en) 1997-07-17
JP2001510321A (ja) 2001-07-31
EP1734122A3 (en) 2007-07-11
US6030945A (en) 2000-02-29
IL125168A (en) 2011-04-28
CA2241572C (en) 2009-08-11
EP0873407B1 (en) 2007-05-23
JP2008308502A (ja) 2008-12-25
JP2007169280A (ja) 2007-07-05
CA2666263A1 (en) 1997-07-17
EP1734122A2 (en) 2006-12-20
IL125168A0 (en) 1999-01-26
HK1018961A1 (en) 2000-01-14
AU729279B2 (en) 2001-02-01
DE69737747T2 (de) 2008-02-14
DE69737747D1 (de) 2007-07-05
AU1824897A (en) 1997-08-01
IL193752A0 (en) 2011-08-01
WO1997025428A1 (en) 1997-07-17
ES2287948T3 (es) 2007-12-16
PT873407E (pt) 2007-09-04
EP0873407A1 (en) 1998-10-28

Similar Documents

Publication Publication Date Title
DE69737747D1 (de) Apo-2 ligand
ATE411385T1 (de) Apo-2 ligand
ATE370232T1 (de) Anti-apo-2 antikörper
IS6322A (is) Viðtaki APRIL (BCMA) og notkun hans
IL133311A0 (en) Imidazolyl-cyclic acetals
DK1032672T3 (da) DNA19355-polypeptid, en tumornekrosefaktor-homolog
DE3382812D1 (de) Neue eiskernformende mikroorganismen
DK1009817T3 (da) RTD-receptor
IT8523143A0 (it) Procedimento per il consolidamento di terreni.
ES2146243T3 (es) Inhibidores de tnf.
DK0939769T3 (da) Vertebrat-Smoothened-proteiner
DK0495910T3 (da) Fremstilling og anvendelse af humant nm23-H2-protein og derimod rettede antistoffer
ATE236983T1 (de) Durch zelldichte stimulierte protein-tyrosin- phosphatasen
IT8521771A0 (it) Dispersione di olio in acqua per uso agricolo.
PT84189A (pt) Improvements relating to solid fuel briquettes
IT8419465A0 (it) Dispersione di carbone in acqua.
SATO Development of PC Precast Slab Pavement Connected with Horn-Joints
IT8419466A0 (it) Dispersione di carbone in acqua.
IT1197846B (it) Coltivazione in serre di tipo idroeroponico
IT8521286U1 (it) Stufa, per il riscaldamento di ambienti, comprendente mezzi per ottenere elevati rendimenti.
KR850007361A (ko) 사조로된 저온 발열판
KR850005112U (ko) 농산폐기물을 연료로 이용하는 흙벽돌 난로
IT1175225B (it) Procedimento per ridurre la quantita' di combustibile necessaria per cuocere i laterizi nelle fornaci